Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953418 | 0.92 | ALOX15 (0.85) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL4515060 | 0.92 | ALOX15 (0.85) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL24672614 | 0.91 | ALOX15 (0.82) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL5151262 | 0.91 | ALOX15 (0.82) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL18325377 | 0.90 | ALOX15 (0.81) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL807358 | 0.90 | ALOX15 (0.81) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL4731563 | 0.88 | ALOX15 (0.79) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL6484067 | 0.88 | ALOX15 (0.79) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL5709857 | 0.88 | ALOX15 (0.79) | ALOX15HTR1DHTR1BTAAR1EGLN1 | |
| SCHEMBL7278898 | 0.87 | ALOX15 (0.76) | ALOX15HTR1DHTR1BEGLN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | XPO1, XPOT, DDB1 | ALOX15 4712/4885HTR1D 4190/4885HTR1B 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.